Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01302808 · ClinicalTrials.gov registry record · Phase 1
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT01302808 is a Phase 1 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 17 participants.
The verdict
NCT01302808, a Phase 1 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
RATIONALE: Romidepsin and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of romidepsin when given together with erlotinib hydrochloride and to see how well they work in treating patients with stage III or stage IV non-small cell lung cancer.
Interventions
- COMBINATION_PRODUCT Erlotinib plus Romidepsin (8 mg/m^2)
- COMBINATION_PRODUCT Erlotinib plus Romidepsin (10 mg/m^2)
- COMBINATION_PRODUCT Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis
- COMBINATION_PRODUCT (Erlotinib plus Romidepsin (8mg/m^2)) + Antiemetic prophylaxis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-09 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01302808
The ClinicalTrials.gov registry entry for NCT01302808 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Erlotinib plus Romidepsin (8 mg/m^2) is the first listed.
NCT01302808 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01302808 about?
NCT01302808 is a clinical study titled "Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer". RATIONALE: Romidepsin and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of romidepsin when given together with erlotinib hydrochloride and to see how well t...
What is the current status of trial NCT01302808?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2009-09. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01302808?
The interventions under investigation include: Erlotinib plus Romidepsin (8 mg/m^2) (COMBINATION_PRODUCT), Erlotinib plus Romidepsin (10 mg/m^2) (COMBINATION_PRODUCT), Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis (COMBINATION_PRODUCT), (Erlotinib plus Romidepsin (8mg/m^2)) + Antiemetic prophylaxis (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT01302808?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.